US-based biopharmaceutical company NovaRx will present the results from the Phase III trial of Lucanix (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer at the European Society for Medical Oncology (ESMO) ...
Tags: Novarx, Therapeutic Vaccine Trial
US-based biopharmaceutical firm Tracon Pharmaceuticals has started dosing in a Phase Ib clinical of TRC105 for the treatment of patients with metastatic renal cell carcinoma. The trial evaluates the combination of TRC105 and a standard ...
Tags: Tracon, Carcinoma Drug
Cancer Research Technology (CRT), Cancer Research UK's technology development arm, has signed a multi-project alliance agreement with Teva Pharmaceutical Industries (TEVA) to research and develop new cancer drugs, which will help in ...
US-based DiscoveRx’s BioSeek division launched BioMAP panel, a primary human cell-based assay platform, for oncology research. The BioMAP panel comprising primary human cell-based tumor-host model systems allows the researchers to ...
Tags: Oncology Research, Biomap Panel
Champions Oncology (Champions), a developer of advanced technology solutions and services to personalize the development and use of oncology drugs, has signed a new discovery and drug development partnership with Teva Pharmaceutical ...
Tags: Champions Oncology
Dfine, a manufacturer of spinal disease treatment devices, has obtained CE Mark approval for its STAR tumor ablation system, designed to treat painful metastatic spinal tumors. The STAR tumor ablation system uses radiofrequency (RF) ...
Tags: Dfine, Tumor Ablation System
Arch Biopartners (Arch) has received US patent for its brain tumor cell targeting technology, which protects novel synthetic peptides that target and attach human brain tumor initiating cells (BTICs) and invasive glioma cells (IGCs). The ...
The European Medicines Agency (EMA) has received an application from Bayer HealthCare for marketing authorization of its oral multi-kinase inhibitor, regorafenib, for the treatment of patients with gastrointestinal stromal tumors (GlST). ...
Therapeutic antibodies developer AnaptysBio has expanded its proprietary immunotherapy antibody portfolio to add multiple new combination therapies. The company developed a proprietary anti-PD-1 antibody, called ANB011, with key ...
Tags: AnaptysBio, Antibody Portfolio
Clinical-stage company OncoMed Pharmaceuticals has announced the issuance of US patent for methods of treating cancer with its antibody vantictumab (OMP-18R5) through 2029. Targeting and inhibiting the Wnt pathway, Vantictumab was ...
Tags: Vantictumab, OncoMed
Accuray has announced its plans to tap the radiation oncology market in China with the introduction of its CyberKnife and TomoTherapy systems. The CyberKnife and the TomoTherapy systems give clinicians in China the most flexible treatment ...
Tags: Tomotherapy Systems, Cyberknife
Affymetrix has launched a whole-genome copy number assay for highly degraded FFPE solid tumor samples, called OncoScan FFPE assay kit, at Chicago. The new OncoScan FFPE assay kit with its unique molecular inversion probe (MIP) technology ...
Tags: Affymetr, FFPE solid tumor samples
Castle Biosciences has announced that data from studies of its DecisionDx-Melanoma test confirm previous studies, indicating that the gene expression profile test is a strong predictor for classifying which Stage I or II non-metastatic ...
Contract research organization Genewiz has partnered with biotechnology company BeiGene to accelerate cancer biomarker discovery to support drug target identification Under the deal, BeiGene will leverage OncoGxOne discovery cancer panels ...
Tags: Genewiz, Beigene, Cancer Biomarker Discovery
Trovagene has adopted RainDance's RainDrop Digital PCR System for research and development, and for use in the Trovagene CLIA laboratory. In addition, Trovagene has successfully developed a cell-free DNA mutation assay leveraging the ...
Tags: Trovagene, Digital PCR System